Hexachlorophene for the Treatment of ParkinsonΓÇÖs Disease and Related Disorders
Reduction in endogenous LRRK2 protein levelsReduction in mutant LRRK2 protein levels
therapeutic agent for Parkinson's disease, Crohn's disease, and related disorders
Mutations in the LRRK2 protein have been linked as one of the causative agents for the pathogenesis of PD and Crohn's disease. Currently, limited options exist for the treatment of these diseases and there is a need to find therapeutic agents that can target LRRK2.In different cell models that overexpress wild-type, mutant, or endogenous LRRK2 protein, treatment with hexachlorophene reduced not only total endogenous LRRK2 but also overexpressed wild-type and mutant LRRK2. Therefore, hexachlorophene has the potential to serve as a treatment option for PD and other related disorders.
美國
